Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 2Other hematologic neoplasm 2Other neoplasm 1Myeloid 1

Conditions

Advanced Malignant Neoplasm 1

Interventions

fludarabine phosphate 2Whole-Body Irradiation 2Peripheral Blood Stem Cell Transplantation 2Mycophenolic Acid 2Docetaxel 2thymoglobulin 1ruxolitinib 1fludarabine 1alethine 1Stem Cell Transplantation 1Sirolimus 1Phenytoin 1Methotrexate 1Irinotecan 1Infusions, Intravenous 1Ifosfamide 1High-Intensity Focused Ultrasound Ablation 1Hematopoietic Stem Cell Transplantation 1Granulocyte Colony-Stimulating Factor 1Erlotinib Hydrochloride 1Endoscopy, Digestive System 1Endoscopy 1Cyclosporine 1Cyclophosphamide 1Celecoxib 1Carboplatin 1CPI-0610 1Busulfan 1Antilymphocyte Serum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Infusions, Intravenous × Other neoplasm × Clear all
NCT05048160 2022-05-09

A Clinical Study of 6MW3211 Injection in the Treatment of Advanced Malignant Neoplasm

Mabwell (Shanghai) Bioscience Co., Ltd.

Phase 1/2 Unknown
272 enrolled
Other neoplasm

Advanced Malignant Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡